



# Prevalence of Extended-Spectrum $\beta$ -Lactamases Among *Klebsiella pneumoniae* Isolated from Intensive Care Unit Patients in a Tertiary Hospital

Shahin Najar-Peerayeh<sup>1</sup>, Safoura Derakhshan<sup>2,\*</sup>, Fatemeh Fallah<sup>3</sup>, Bita Bakhshi<sup>1</sup> and Masoud Alebouyeh<sup>4,5</sup>

<sup>1</sup>Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

<sup>2</sup>Liver and Digestive Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

<sup>3</sup>Pediatric Infections Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>4</sup>Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>5</sup>Pediatric Infections Research Center (PIRC), Research Institute for Children Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

\*Corresponding author: Department of Microbiology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Email: s.derakhshan@muk.ac.ir

Received 2018 April 08; Revised 2018 October 07; Accepted 2018 November 05.

## Abstract

**Background:** The increased prevalence of extended-spectrum  $\beta$ -lactamases (ESBLs)-producing virulent strains possibly leads to serious outbreaks in hospitals.

**Objectives:** The aims of the study were to detect ESBLs in *Klebsiella pneumoniae* isolated from patients in intensive care units (ICUs) of a hospital and to investigate their genetic relationships.

**Methods:** A total number of 85 *K. pneumoniae* isolates were detected in the specimens of ICU patients in a tertiary hospital in the southwest of Tehran, Iran. Antibiotic susceptibility was determined by the disk diffusion method. The *rmpA* and *wcaG* virulence genes were detected by polymerase chain reaction (PCR). The ESBL-positive isolates were typed using multilocus variable-number tandem repeat analysis (MLVA) method.

**Results:** Of the 85 *K. pneumoniae* isolates, 48 (56.5%) produced ESBLs. There were statistically significant differences in the prevalence of virulence genes based on ESBL production. The typing of the 48 ESBL-positive isolates showed a significant genetic relatedness with the identification of nine MLVA types.

**Conclusions:** This study showed a relatively high prevalence of ESBL in *K. pneumoniae* isolated from ICU patients and a low diversity between these isolates. The selection of ESBL-producing clones was mainly responsible for the spread of *K. pneumoniae* in the ICUs.

**Keywords:** Beta-Lactamases, *Klebsiella pneumoniae*, Molecular Typing

## 1. Background

Antibiotic resistance in pathogens is a growing problem in all parts of the world, making infectious diseases difficult to treat. *Klebsiella pneumoniae* is one of the predominant drug-resistant gram-negative pathogens associated with nosocomial infections, particularly in intensive care units (ICUs) (1). The extensive use of antibiotics in ICUs to treat infections and selective antibiotic pressure, particularly due to the intensive use of extended-spectrum cephalosporins, can lead to the selection and dissemination of extended-spectrum  $\beta$ -lactamase (ESBL)-producing *K. pneumoniae* (2). ESBLs are usually plasmid-mediated enzymes, which confer resistance to ceftazidime, cefotaxime, and other extended-spectrum cephalosporins and

monobactams (1).

Resistance to antimicrobial agents is often associated with the spread of mobile genetic elements, which may also harbor virulence determinants (3). The polysaccharide capsule is the most important virulence factor in *K. pneumoniae* and confers a mucoid phenotype to the isolates. The plasmid gene *rmpA* (regulator of mucoid phenotype A) increases the extracapsular polysaccharide synthesis in *K. pneumoniae* and results in the hypermucoviscous phenotype (4, 5). The *wcaG* virulence gene encodes the capsular fucose synthesis and enhances the ability of bacteria to evade phagocytosis by macrophages (6). The *rmpA* gene is found on plasmids (5) and the *wcaG* on the transferable regions of a chromosome responsible for capsule biosynthesis (6); therefore, there is a probability of hori-

zonal transfer of both genes. The acquisition of virulence and resistance traits may provide a strong benefit for the survival of the microorganism and may lead to severe epidemic infectious diseases (3).

Large outbreaks caused by the clonal transmission of ESBL-producing *K. pneumoniae* and/or the horizontal transfer of mobile genetic elements carrying ESBL genes have been reported, particularly in ICUs (7, 8). Epidemiological studies of the spread of *K. pneumoniae* depend on the availability of sensitive tests that provide sufficient discrimination between strains. Pulsed-field gel electrophoresis (PFGE) of genomic DNA is a highly discriminating typing method and has frequently been used to type ESBL-producing *K. pneumoniae* strains (8, 9). However, the comparison of isolates by PFGE encounters several limitations, including the cost of the special equipment needed and the poor reproducibility between laboratories (10). Newer molecular typing methods are commonly used, and have been proven useful for epidemiological studies (11-13). MLVA (multiple-locus variable-number tandem-repeat analysis) is a PCR-based typing method that involves the analysis of variable-number tandem-repeat (VNTR) sequences. VNTRs are repeated sequences that vary in copy numbers even among highly related bacterial strains. The analysis of multiple VNTRs enables high-resolution genotyping. For a selected set of tandem repeats, the comparison of copy numbers between bacterial strains can provide insights into relationships between strains (12). Turton et al. described a nine-locus MLVA scheme with high discriminatory power for typing of *K. pneumoniae* (14, 15). This is the most commonly used MLVA scheme for typing of *K. pneumoniae* to date (15-18).

## 2. Objectives

In the present study, we investigated the presence of ESBLs and the *rmpA* and *wcaG* virulence genes in *K. pneumoniae* isolated from patients admitted to the ICUs of a tertiary care hospital in Tehran, Iran. Furthermore, the epidemiological relationships between ESBL-producing *K. pneumoniae* were studied by the MLVA method.

## 3. Methods

### 3.1. Bacterial Isolates and Antimicrobial Susceptibility Testing

A total number of 85 *K. pneumoniae* isolates were collected from different clinical specimens of patients admitted to the ICUs of a hospital in the southwest of Tehran, Iran. This hospital is a 420-bed teaching tertiary and referral poison treatment center with a nearly annual average of 20000 admissions and outpatient visits. The isolates were identified using biochemical tests, including

triple-sugar-iron, urease, Voges-Proskauer, methyl-red, citrate utilization, indole production, and motility (19).

Antibiotic susceptibility was determined using the disk diffusion method on Mueller-Hinton agar (Merck, Germany) as recommended by the 2016 Clinical and Laboratory Standard Institute (CLSI) (20). Susceptibility was tested toward 14 antibiotics (Mast, UK): cefotaxime (Ctx, 30  $\mu$ g), ceftriaxone (Cro, 30  $\mu$ g), ceftazidime (Caz, 30  $\mu$ g), imipenem (Ipm, 10  $\mu$ g), amoxicillin-clavulanic acid (Aug, 30  $\mu$ g), aztreonam (Atm, 30  $\mu$ g), ciprofloxacin (Cip, 5  $\mu$ g), tobramycin (Tn, 10  $\mu$ g), tetracycline (T, 30  $\mu$ g), trimethoprim-sulfamethoxazole (Ts, 25), gentamicin (Gm, 10  $\mu$ g), cefepime (Cpm, 30  $\mu$ g), ceftoxitin (Fox, 30  $\mu$ g), and amikacin (Ak, 30  $\mu$ g). *Escherichia coli* ATCC 25922 was used as a quality control strain.

### 3.2. Phenotypic Detection of ESBL

The isolates with reduced-susceptibility to any of the tested third-generation cephalosporins (ceftazidime, ceftriaxone, and cefotaxime) were analyzed by the combination disk method using ceftazidime (30  $\mu$ g), ceftazidime/clavulanic acid (30/10  $\mu$ g), cefotaxime (30  $\mu$ g), and cefotaxime/clavulanic acid (30/10  $\mu$ g) according to the CLSI guidelines (20). The inoculum and incubation conditions were the same as those for the disk diffusion. ESBL production was confirmed if inhibitory zones of the disks with clavulanic acid were  $\geq$  5 mm larger than the zones without the inhibitor. *K. pneumoniae* ATCC 700603 was used as an ESBL positive control and *E. coli* ATCC 25922 as a negative control.

### 3.3. DNA Extraction and Detection of Virulence Genes

The presence of *rmpA* and *wcaG* genes was detected by polymerase chain reaction (PCR). Genomic DNA was prepared by the freeze-thaw method and used as the template for PCR reactions. Briefly, overnight broth cultures of the isolates were centrifuged and Tris-EDTA (TE) buffer was added to the pellets. The suspensions were boiled at 100°C for 10 min and then immediately placed on ice for 5 min. After three cycles of freezing/thawing, the tubes were centrifuged and the supernatants were stored at -20°C as DNA templates.

Amplification was performed as a duplex-PCR on Gene Amp PCR System PTC-1148 (Biorad, USA) using published primer pairs for *rmpA*: 5'-ACTGGGCTACCTCTGCTTCA-3', 5'-CTTGATGAGCCATCTTTCA-3' (amplicon size: 516 bp) (21) and *wcaG*: 5'-GGTTGGKTCAGCAATCGTA-3', 5'-ACTATCCGCCAAGCTTTTGC-3' (amplicon size: 169 bp) (14). PCRs were performed in a volume of 25  $\mu$ L containing 1X PCR buffer, 1.5 mM MgCl<sub>2</sub>, 0.4  $\mu$ M of each primer, 200  $\mu$ M each dNTP, 1 U Taq DNA polymerase (Fermentas, Germany),

and 3  $\mu$ L of DNA extract. Cycling conditions included initial denaturation at 94°C for 5 min, 35 subsequent cycles of 1 min at 94°C, 1 min at 54°C, and 1 min at 72°C with a final elongation at 72°C for 7 min. The PCR products were analyzed by electrophoresis on a 1% agarose gels in 1X TAE (Tris-Acetate-EDTA) buffer. The gels were stained with ethidium bromide and the PCR products were visualized under UV light.

### 3.4. Molecular Typing

The ESBL-positive isolates were typed by the MLVA method. The primers targeting the 5' and 3' flanking regions of nine VNTR loci (A, E, H, J, K, D, N1, N2, and N4) were used for amplification (Table 1) (14, 15). PCRs were performed in a total reaction volume of 25  $\mu$ L containing 1X PCR buffer, 1.5 mM MgCl<sub>2</sub>, 0.4  $\mu$ M of each primer, 200  $\mu$ M each dNTP, 1 U Taq DNA polymerase (Fermentas, Germany), and 3  $\mu$ L of DNA extract. Thermocycler conditions were 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 1 min, annealing at 52°C for 1 min (except loci H, E, and J for which the annealing temperature was 55°C), extension at 72°C for 1 min, and a final extension at 72°C for 7 min. The amplified products were separated on a 1.5% agarose gel in 0.5X TBE (Tris-Borate-EDTA) buffer and run at 8 V/cm for 5 h. The gels were stained with ethidium bromide for 15 to 30 min, then rinsed with water, and visualized under UV light.

The size of each PCR product was estimated by comparison with a size ladder. Amplicon sizes were converted into repeat numbers. Repeat numbers were then rounded up or down as appropriate and were recorded in the order of loci A, E, H, J, K, D, N1, N2, and N4, giving the VNTR profile.

A minimum spanning tree (MST) was constructed based on allelic profiles of the strains using the online tool available at <http://mlvaplus.net>. A new genotype number was given when one difference was observed at any VNTR. Clones were designated as a group of isolates with indistinguishable VNTR profiles. Clonal complexes were defined as groups of isolates for which the genotypes did not differ in more than two VNTR loci (22).

### 3.5. Statistical Analysis

The data were analyzed using the Pearson chi-square test or Fisher's exact test and a P value of < 0.05 was considered to indicate statistical significance. The employed statistical software was SPSS 16.0 (SPSS, Chicago, USA). The discriminatory power of MLVA was determined by Simpson's index of diversity using a freely available online tool comparing partitions available at <http://Darwin.phylovis.net/ComparingPartitions>.

**Table 1.** Primer Sequences for Amplification of VNTR Loci and Their Corresponding Period and Flanking Sequence Sizes in *K. pneumoniae* MGH 78578

VNTR Locus, Primer Sequence (5' to 3')	Period Size (bp)	Size of Flanking Sequence (bp)
<b>D</b>	14	119
GCAGGTCTCGTCTTCATTCC		
TGACCATCGAAGAGGCG		
<b>K</b>	118	151
GAGCTGGGGCTGGAATA		
GCAATCTGCCCGAAATA		
<b>A</b>	140	129
AGCGTATCTGCCATTGCC		
CAGCATGGCCAGTTTGTCT		
<b>E</b>	118	79
CCAAATCCGGGTATTATCG		
TTCGATACCCATCCGGAAG		
<b>H</b>	124	134
ATGACCAAGGAAGAACCCG		
CTTACCTGGCATGCGAACG		
<b>J</b>	124	118
ACCGGATTAAGCGTATTCC		
TTCCTGCCCCACGGATAG		
<b>N1</b>	116	107
CATCAGGTGCAAGATTCCA		
TGAGCGATTGCTGCCTA		
<b>N2</b>	57	109
GATGCGGCAAGCACAC		
ACGCCCTGACCATTATGC		
<b>N4</b>	67	119
GTGCGGTGATTGTGATGG		
CTGACAACGTCGATGTGG		

## 4. Results


A total number of 85 *K. pneumoniae* isolates were collected from different clinical specimens of ICU patients in a tertiary hospital. Of the 85 isolates, 71 (83.5%) were obtained from tracheal secretions and 14 (16.5%) from urine. Twenty-nine isolates (34.1%) were from females and 56 (65.9%) from males. The analysis of antimicrobial susceptibility profile showed that all isolates, but one, were susceptible to imipenem (98.8%). Of the 85 isolates, 83 were susceptible to cefoxitin (97.6%), 72 to tetracycline (84.7%), 49 to amikacin (57.6%), 40 to gentamicin (47%), 38 to aztreonam and trimethoprim-sulphamethoxazole (44.7%, each), 37 to cefotaxime, ceftriaxone, ceftazidime, cefepime, and tobramycin (43.5%, each), 36 to ciprofloxacin (42.3%), and 34 to amoxicillin-clavulanic acid (40%). The combination disk method confirmed 56.5% of the isolates (48/85) as ESBL producers. Of these 48 ESBL-producing isolates, 45 (93.7%) were isolated from tracheal secretions and three (6.2%) from urine samples. The ESBL production was more prevalent in males than in females [(36/48, 75%) vs. (12/48, 25%), respectively].

Of the 85 isolates, the *rmpA* and *wcaG* genes were detected in 45 isolates (52.9%); *rmpA* was detected in seven

(8.2%) and *wcaG* in 40 (47%) isolates. Two isolates featured both virulence genes. The prevalence of *rmpA* was one in the 48 ESBL-producing isolates and six in the 37 ESBL-negative isolates. There was a significant relationship between the presence of *wcaG* and production of ESBL ( $P < 0.05$ ). The 48 ESBL-positive isolates showed a higher prevalence of *wcaG* compared to the 37 ESBL-negative isolates (34 vs. 6, respectively;  $P < 0.001$ ).


#### 4.1. MLVA Assay

Using any band difference in a profile to designate MLVA types, the analysis revealed nine MLVA types among the 48 ESBL-producing isolates. The discriminatory power of MLVA was 0.520 (Simpson's diversity index) with a 95% confidence interval of 0.351 - 0.689. The MLVA assay setup for two VNTR loci is shown in Figure 1.



**Figure 1.** Polymorphism of two VNTR loci in *K. pneumoniae* isolates. The number of repeats for each VNTR locus can be directly estimated by comparison with a size ladder. L., 50 bp DNA ladder.

To examine the relatedness among the identified MLVA types, an MST analysis was performed based on the categorical datasets (Figure 2). Two clonal complexes and five singletons were identified. Complex 1 was composed of two MLVA types 1 and 4, and contained two and five isolates, respectively. These types showed the same virulence gene profile as *rmpA* (-)*wcaG* (-) and the similarity between the two types was above 70%. Complex 2 was composed of two MLVA types 20 and 18, and contained one and two isolates, respectively. These types also showed the same virulence gene profile as *rmpA* (-)*wcaG* (-) and the similarity between the two types was above 70%. The largest clone (marked with an asterisk) contained the largest number of strains ( $n = 33$ ). All of these 33 isolates were *rmpA* (-)*wcaG* (+), shared the same VNTR profile (3, 5, 2, 8, 0.5, 1, 4, 5, 1, MT7), and showed the same antibiotic resistance pattern. The size of some amplicons was similar to the flanking sequences; hence, the number of repeats was designated by zero. The null allele was reported when no product was detected at that locus. Some alleles were reported as half size, which may result from the presence of intermediately



**Figure 2.** Minimum spanning tree for 48 isolates of ESBL-producing *Klebsiella pneumoniae*. Each circle represents a unique MLVA type and the type number was indicated within the circle; the size of the circles indicates the number of isolates. Clonal complexes were indicated by rectangles surrounding the MLVA types. Complexes were assigned if two neighboring types did not differ in more than two VNTR loci. A dotted line indicates allelic differences at five VNTR loci. The largest clone shown with an asterisk contained the largest number of strains.

sized repeat units or small deletions in the flanking sequences.

The resistance profile and virulence gene contents of each MLVA type together with the number of repeats at each VNTR locus are presented in Table 2. The MT7 was the most commonly found MLVA type representing 68.7% (33/48) of the isolates (Table 2).

**Table 2.** Antimicrobial Resistance Patterns of 48 Isolates of ESBL-Producing *Klebsiella pneumoniae* Along with Isolates Numbers, Their Association with Sample, Virulence Genes, and Respective MLVA Type

MLVA Type	VNTR Profile <sup>a</sup>	<i>rmpA</i>	<i>wcaG</i>	Sample	Number of Isolates	Resistance Profile <sup>b</sup>
7	3, 5, 2, 8, 0, 5, 1, 4, 5, 1	(-)	(+)	Urine	1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, Ts, Gm, Cpm, Ak
				Trachea	32	
4	3, 3, 3, 0, 1, 1, 4, 1, 1	(-)	(-)	Urine	1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, T, Ts, Gm, Cpm
				Trachea	3	
				Trachea	1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, T, Ts, Cpm
1	6, 3, 4, 5, 0, 1, 1, 4, 1, 1	(-)	(-)	Trachea	1	Ctx, Cro, Caz, Ipm, Aug, Atm, Cip, Tn, T, Ts, Gm, Cpm, Fox, Ak
					1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, Ts, Gm, Cpm
39	- , 8, -, 1, 1, 2, 4, 1, 1	(-)	(-)	Trachea	1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, T, Ts, Gm, Cpm
16	3, 2, 6, 2, 1, 1, 1, 3, 1	(+)	(-)	Trachea	1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, T, Ts, Gm, Cpm
18	1, 5, 3, 5, 5, 2, 2, 3, 3, 1	(-)	(-)	Urine	1	Ctx, Cro, Caz, Aug, Atm, Cip, Cpm, Ak
				Trachea	1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, T, Ts, Cpm
20	4, 5, 3, 5, 5, 2, 2, 2, 3, 1	(-)	(-)	Trachea	1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, Ts, Gm, Cpm
31	2, 3, -, 5, 5, 0, 5, 2, 4, 3, 1	(-)	(-)	Trachea	1	Ctx, Cro, Caz, Aug, Cip, Tn, T, Ts, Gm, Cpm
					1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, Ts, Cpm
23	6, -, 4, 5, 5, 5, 10, 2, 2, 2, 1	(-)	(+)	Trachea	1	Ctx, Cro, Caz, Aug, Atm, Cip, Tn, Gm, Cpm

Abbreviations: Ak, amikacin; Atm, aztreonam; Aug, amoxicillin-clavulanate; Caz, ceftazidime; Cip, ciprofloxacin; Cpm, cefepime; Cro, ceftriaxone; Ctx, cefotaxime; Fox, cefoxitin; Gm, gentamicin; T, tetracycline; Tn, tobramycin; Trachea, Tracheal secretions; Ts, trimethoprim-sulphamethoxazole; (-), negative; (+), positive.

<sup>a</sup> VNTR profiles are indicated in the order of loci A, E, H, J, K, D, Ni, N2, and N4. PCR products that contained no repeats were designated by '0'. A dash (-) in the VNTR profile indicates that no band was detected at that locus.

<sup>b</sup> The resistance profiles included antimicrobial agents that exhibited intermediate resistance.

## 5. Discussion

The rapidly increasing number of ESBL-producing *K. pneumoniae* isolates, particularly in high-risk wards such as ICUs, and the continuous influx of strains from hospital settings to the community can lead to serious problems in clinical settings and public health (1, 2). More than half of our strains from ICU patients (56.5%) were ESBL-producers, which is in agreement with other reports (23, 24).

*K. pneumoniae* strains with ESBL-production and virulence characteristics complicate the management of infections and might explain the persistence and spread of particular clones within and between hospitals. Virulence factors related to the capsule play important roles in the pathogenicity of *K. pneumoniae* infections (4, 5); for example, *rmpA* confers a highly mucoviscous phenotype by enhancing extracapsular polysaccharide synthesis (5) and

*wcaG* encodes capsular fucose synthesis and enhances the capacity to escape phagocytosis by macrophages (6). The *rmpA* gene has been found to be located on plasmids (5) and *wcaG* on the transferable regions of a chromosome responsible for capsule biosynthesis (6); therefore, there is a probability of horizontal transfer of both genes. Horizontal gene transfer is probably the most important mechanism for dissemination of virulence and resistance determinants and co-selection of virulence and resistance properties in bacteria (3). We found statistically significant differences in the prevalence of the *wcaG* virulence genes according to the ESBL production. Several studies have shown a correlation between the production of ESBL and virulence factors; for example, ESBL-producing isolates of *K. pneumoniae* were shown to produce stronger biofilms, as well as to be more invasive and more resistant to the bactericidal activity of serum (25); moreover, resistance to

quinolones in *E. coli* isolates has been associated with the loss of virulence factors (3).

The acquisition of resistance determinants by virulent strains may lead to long persistence and dissemination of microorganisms in clinical settings. With the aim of monitoring the dissemination of ESBL-producing isolates from the ICUs of our hospital, we performed a molecular MLVA typing on the 48 ESBL-positive *K. pneumoniae* isolates from ICU patients, based on the previously reported VNTR loci (14, 15). The MLVA data revealed the presence of a significant genetic relatedness between the isolates with the identification of nine MLVA types, possibly reflecting antibiotic selective pressure. Antibiotic selection leads to less diversity of population structure while antibiotic-free environments allow for competition and lead to diverse non-related population structure (1, 26). The ESBL-population is likely a more selected group and a more homogenous population, allowing us to detect less diversity and few MLVA types in this group, in agreement with other reports (26, 27). For example, Hertz et al. showed that the susceptible *Escherichia coli* population was a much more diverse group than the ESBL-producing *E. coli* populations (26). The majority of our strains belonged to one major clone (MLVA type 7) showing the vertical transmission of resistant isolates and low level of infection control practices in these units. Indeed, ICU patients are ideal reservoirs for the acquisition of ESBL-producing *K. pneumoniae*, because, in these wards, patients are exposed to a large number of potential risk factors for infection by these strains (2). Some isolates did not demonstrate the clonal spread and dissemination of these strains was likely due to the transfer of mobile genetic elements (e.g. plasmids) harboring ESBL genes (26).

Several different methods have been used for genotyping of *K. pneumoniae* (8, 11, 12). Although, for many years, PFGE has been the excellent typing method because of its discriminatory power (28-30), the comparison of isolates by PFGE is faced with several limitations, including the cost of the special equipment needed and poor reproducibility between laboratories, making it unsuitable for comparison between laboratories (10). In contrast to PFGE, MLVA is a PCR-based typing method that requires only basic equipment and allows interlaboratory comparison of results (12). However, studies using MLVA for the typing of ESBL-producing *K. pneumoniae* remain limited, with a few published studies (16-18, 27, 31-33). On the other hand, with the development of techniques that allow for sequencing of bacterial chromosomes in a short time and detection of more helpful repetitive targets, MLVA may indeed be a useful method for typing, particularly for laboratories with inadequate laboratory equipment.

In conclusion, this study gave insights into the rela-

tively high prevalence of ESBLs in *K. pneumoniae* isolated from the ICUs and genetic backgrounds of these strains. Due to some limitations, we could not trace the clonal spread of our isolates; moreover, the origin of suspected transmission and the possibility of a common source of infection within the units or from an unidentified environmental source remained unknown. The increasing prevalence of ESBL-producing strains of *K. pneumoniae* worldwide and co-existence of resistance and virulence determinants will likely lead to serious potential outbreaks and generate increasing demands for rapid and simple typing techniques with high discriminatory power. The rapidity and simplicity of interpretation of MLVA make it suitable for bacterial typing, preferably for smaller diagnostic laboratories.

## Footnotes

**Authors' Contribution:** Shahin Najar-Peerayeh designed the study. Safoura Derakhshan performed microbiological and molecular studies. Fatemeh Fallah and Bita Bakhshi advised the project. Safoura Derakhshan and Masoud Alebouyeh prepared the manuscript. All authors approved the final manuscript.

**Ethical Considerations:** Not required.

**Funding/Support:** None to declare.

## References

1. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. *Clin Microbiol Rev.* 2005;**18**(4):657-86. doi: [10.1128/CMR.18.4.657-686.2005](https://doi.org/10.1128/CMR.18.4.657-686.2005). [PubMed: [16223952](https://pubmed.ncbi.nlm.nih.gov/16223952/)]. [PubMed Central: [PMC1265908](https://pubmed.ncbi.nlm.nih.gov/PMC1265908/)].
2. Asensio A, Oliver A, Gonzalez-Diego P, Baquero F, Perez-Diaz JC, Ros P, et al. Outbreak of a multiresistant *Klebsiella pneumoniae* strain in an intensive care unit: Antibiotic use as risk factor for colonization and infection. *Clin Infect Dis.* 2000;**30**(1):55-60. doi: [10.1086/313590](https://doi.org/10.1086/313590). [PubMed: [10619733](https://pubmed.ncbi.nlm.nih.gov/10619733/)].
3. Da Silva GJ, Mendonca N. Association between antimicrobial resistance and virulence in *Escherichia coli*. *Virulence.* 2012;**3**(1):18-28. doi: [10.4161/viru.3.1.18382](https://doi.org/10.4161/viru.3.1.18382). [PubMed: [22286707](https://pubmed.ncbi.nlm.nih.gov/22286707/)].
4. Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev.* 1998;**11**(4):589-603. [PubMed: [9767057](https://pubmed.ncbi.nlm.nih.gov/9767057/)]. [PubMed Central: [PMC88898](https://pubmed.ncbi.nlm.nih.gov/PMC88898/)].
5. Cheng HY, Chen YS, Wu CY, Chang HY, Lai YC, Peng HL. RmpA regulation of capsular polysaccharide biosynthesis in *Klebsiella pneumoniae* CG43. *J Bacteriol.* 2010;**192**(12):3144-58. doi: [10.1128/JB.00031-10](https://doi.org/10.1128/JB.00031-10). [PubMed: [20382770](https://pubmed.ncbi.nlm.nih.gov/20382770/)]. [PubMed Central: [PMC2901686](https://pubmed.ncbi.nlm.nih.gov/PMC2901686/)].
6. Shu HY, Fung CP, Liu YM, Wu KM, Chen YT, Li LH, et al. Genetic diversity of capsular polysaccharide biosynthesis in *Klebsiella pneumoniae* clinical isolates. *Microbiology.* 2009;**155**(Pt 12):4170-83. doi: [10.1099/mic.0.029017-0](https://doi.org/10.1099/mic.0.029017-0). [PubMed: [19744990](https://pubmed.ncbi.nlm.nih.gov/19744990/)].
7. Messai Y, Ibadene H, Benhassine T, Alouache S, Tazir M, Gautier V, et al. Prevalence and characterization of extended-spectrum beta-lactamases in *Klebsiella pneumoniae* in Algiers

- hospitals (Algeria). *Pathol Biol (Paris)*. 2008;**56**(5):319-25. doi: [10.1016/j.patbio.2008.05.008](https://doi.org/10.1016/j.patbio.2008.05.008). [PubMed: [18585867](https://pubmed.ncbi.nlm.nih.gov/18585867/)].
8. Mena A, Plasencia V, Garcia L, Hidalgo O, Ayestarán JI, Alberti S, et al. Characterization of a large outbreak of CTX-M-1-producing *Klebsiella pneumoniae* and mechanisms leading to in vivo carbapenem resistance development. *J Clin Microbiol*. 2006;**44**(8):2831-7. doi: [10.1128/JCM.00418-06](https://doi.org/10.1128/JCM.00418-06). [PubMed: [16891499](https://pubmed.ncbi.nlm.nih.gov/16891499/)]. [PubMed Central: [PMC1594597](https://pubmed.ncbi.nlm.nih.gov/PMC1594597/)].
  9. Lytsy B, Sandegren L, Tano E, Torell E, Andersson DI, Melhus A. The first major extended-spectrum beta-lactamase outbreak in Scandinavia was caused by clonal spread of a multiresistant *Klebsiella pneumoniae* producing CTX-M-15. *APMIS*. 2008;**116**(4):302-8. doi: [10.1111/j.1600-0463.2008.00922.x](https://doi.org/10.1111/j.1600-0463.2008.00922.x). [PubMed: [18397465](https://pubmed.ncbi.nlm.nih.gov/18397465/)].
  10. Sekse C, Sunde M, Lindstedt BA, Hopp P, Bruheim T, Cudjoe KS, et al. Potentially human-pathogenic *Escherichia coli* O26 in Norwegian sheep flocks. *Appl Environ Microbiol*. 2011;**77**(14):4949-58. doi: [10.1128/AEM.00189-11](https://doi.org/10.1128/AEM.00189-11). [PubMed: [21642413](https://pubmed.ncbi.nlm.nih.gov/21642413/)]. [PubMed Central: [PMC3147382](https://pubmed.ncbi.nlm.nih.gov/PMC3147382/)].
  11. Dumpis U, Iversen A, Balode A, Saule M, Miklasevics E, Giske CG. Outbreak of CTX-M-15-producing *Klebsiella pneumoniae* of sequence type 199 in a Latvian teaching hospital. *APMIS*. 2010;**118**(9):713-6. doi: [10.1111/j.1600-0463.2010.02640.x](https://doi.org/10.1111/j.1600-0463.2010.02640.x). [PubMed: [20718724](https://pubmed.ncbi.nlm.nih.gov/20718724/)].
  12. Gierczynski R, Golubov A, Neubauer H, Pham JN, Rakin A. Development of multiple-locus variable-number tandem-repeat analysis for *Yersinia enterocolitica* subsp. *palearctica* and its application to bioserogroup 4/O3 subtyping. *J Clin Microbiol*. 2007;**45**(8):2508-15. doi: [10.1128/JCM.02252-06](https://doi.org/10.1128/JCM.02252-06). [PubMed: [17553973](https://pubmed.ncbi.nlm.nih.gov/17553973/)]. [PubMed Central: [PMC1951228](https://pubmed.ncbi.nlm.nih.gov/PMC1951228/)].
  13. Dyet KH, Robertson I, Turbitt E, Carter PE. Characterization of *Escherichia coli* O157:H7 in New Zealand using multiple-locus variable-number tandem-repeat analysis. *Epidemiol Infect*. 2011;**139**(3):464-71. doi: [10.1017/S0950268810001068](https://doi.org/10.1017/S0950268810001068). [PubMed: [20478087](https://pubmed.ncbi.nlm.nih.gov/20478087/)].
  14. Turton JF, Perry C, Elgohari S, Hampton CV. PCR characterization and typing of *Klebsiella pneumoniae* using capsular type-specific, variable number tandem repeat and virulence gene targets. *J Med Microbiol*. 2010;**59**(Pt 5):541-7. doi: [10.1099/jmm.0.015198-0](https://doi.org/10.1099/jmm.0.015198-0). [PubMed: [2010386](https://pubmed.ncbi.nlm.nih.gov/2010386/)].
  15. Morris D, Boyle F, Morris C, Condon I, Delannoy-Vieillard AS, Power L, et al. Inter-hospital outbreak of *Klebsiella pneumoniae* producing KPC-2 carbapenemase in Ireland. *J Antimicrob Chemother*. 2012;**67**(10):2367-72. doi: [10.1093/jac/dks239](https://doi.org/10.1093/jac/dks239). [PubMed: [22744760](https://pubmed.ncbi.nlm.nih.gov/22744760/)].
  16. Drew RJ, Turton JF, Hill RL, Livermore DM, Woodford N, Paulus S, et al. Emergence of carbapenem-resistant Enterobacteriaceae in a UK paediatric hospital. *J Hosp Infect*. 2013;**84**(4):300-4. doi: [10.1016/j.jhin.2013.05.003](https://doi.org/10.1016/j.jhin.2013.05.003). [PubMed: [23831281](https://pubmed.ncbi.nlm.nih.gov/23831281/)].
  17. Jain A, Hopkins KL, Turton J, Doumith M, Hill R, Loy R, et al. NDM carbapenemases in the United Kingdom: An analysis of the first 250 cases. *J Antimicrob Chemother*. 2014;**69**(7):1777-84. doi: [10.1093/jac/dku084](https://doi.org/10.1093/jac/dku084). [PubMed: [24769387](https://pubmed.ncbi.nlm.nih.gov/24769387/)].
  18. Ranjbar R, Memariani H, Sorouri R, Memariani M. Distribution of virulence genes and genotyping of CTX-M-15-producing *Klebsiella pneumoniae* isolated from patients with community-acquired urinary tract infection (CA-UTI). *Microb Pathog*. 2016;**100**:244-9. doi: [10.1016/j.micpath.2016.10.002](https://doi.org/10.1016/j.micpath.2016.10.002). [PubMed: [27725280](https://pubmed.ncbi.nlm.nih.gov/27725280/)].
  19. Forbes BA, Sahm DF, Weissfeld AS. *Bailey and Scott's diagnostic microbiology*. 12th ed. Elsevier Publishing Company; 2007.
  20. Clinical and Laboratory Standards Institute. *Performance standards for antimicrobial susceptibility testing*. 26th ed. CLSI; 2016.
  21. Nadasy KA, Domiati-Saad R, Tribble MA. Invasive *Klebsiella pneumoniae* syndrome in North America. *Clin Infect Dis*. 2007;**45**(3):e25-8. doi: [10.1086/519424](https://doi.org/10.1086/519424). [PubMed: [17599300](https://pubmed.ncbi.nlm.nih.gov/17599300/)].
  22. Vu-Thien H, Corbineau G, Hormigos K, Fauroux B, Corvol H, Clement A, et al. Multiple-locus variable-number tandem-repeat analysis for longitudinal survey of sources of *Pseudomonas aeruginosa* infection in cystic fibrosis patients. *J Clin Microbiol*. 2007;**45**(10):3175-83. doi: [10.1128/JCM.00702-07](https://doi.org/10.1128/JCM.00702-07). [PubMed: [17699654](https://pubmed.ncbi.nlm.nih.gov/17699654/)]. [PubMed Central: [PMC2045346](https://pubmed.ncbi.nlm.nih.gov/PMC2045346/)].
  23. Ghasemi Y, Archin T, Kargar M, Mohkam M. A simple multiplex PCR for assessing prevalence of extended-spectrum beta-lactamases producing *Klebsiella pneumoniae* in intensive care units of a referral hospital in Shiraz, Iran. *Asian Pac J Trop Med*. 2013;**6**(9):703-8. doi: [10.1016/S1995-7645\(13\)60122-4](https://doi.org/10.1016/S1995-7645(13)60122-4). [PubMed: [23827147](https://pubmed.ncbi.nlm.nih.gov/23827147/)].
  24. Sekowska A, Gospodarek E, Kusza K. The prevalence of infections and colonisation with *Klebsiella pneumoniae* strains isolated in ICU patients. *Anaesthesiol Intensive Ther*. 2014;**46**(4):280-3. doi: [10.5603/AIT.2014.0045](https://doi.org/10.5603/AIT.2014.0045). [PubMed: [25293479](https://pubmed.ncbi.nlm.nih.gov/25293479/)].
  25. Gharrah MM, Mostafa El-Mahdy A, Barwa RF. Association between virulence factors and extended spectrum beta-lactamase producing *klebsiella pneumoniae* compared to nonproducing isolates. *Interdiscip Perspect Infect Dis*. 2017;**2017**:7279830. doi: [10.1155/2017/7279830](https://doi.org/10.1155/2017/7279830). [PubMed: [28684959](https://pubmed.ncbi.nlm.nih.gov/28684959/)]. [PubMed Central: [PMC5480045](https://pubmed.ncbi.nlm.nih.gov/PMC5480045/)].
  26. Hertz FB, Nielsen JB, Schonning K, Littauer P, Knudsen JD, Lobner-Olesen A, et al. Population structure of drug-susceptible,-resistant and ESBL-producing *Escherichia coli* from community-acquired urinary tract. *BMC Microbiol*. 2016;**16**:63. doi: [10.1186/s12866-016-0681-z](https://doi.org/10.1186/s12866-016-0681-z). [PubMed: [27067536](https://pubmed.ncbi.nlm.nih.gov/27067536/)]. [PubMed Central: [PMC4827192](https://pubmed.ncbi.nlm.nih.gov/PMC4827192/)].
  27. Heffernan H, Dyet KH, Woodhouse R, Williamson D. *Antimicrobial susceptibility and molecular epidemiology of extended-spectrum beta-lactamase producing Enterobacteriaceae in New Zealand*. 2013. 2014.
  28. Cookson BD, Robinson DA, Monk AB, Murchan S, Deplano A, de Ryck R, et al. Evaluation of molecular typing methods in characterizing a European collection of epidemic methicillin-resistant *Staphylococcus aureus* strains: The HARMONY collection. *J Clin Microbiol*. 2007;**45**(6):1830-7. doi: [10.1128/JCM.02402-06](https://doi.org/10.1128/JCM.02402-06). [PubMed: [17428929](https://pubmed.ncbi.nlm.nih.gov/17428929/)]. [PubMed Central: [PMC1933060](https://pubmed.ncbi.nlm.nih.gov/PMC1933060/)].
  29. Schouls LM, Spalburg EC, van Luit M, Huijsdens XW, Pluister GN, van Santen-Verheuevel MG, et al. Multiple-locus variable number tandem repeat analysis of *Staphylococcus aureus*: Comparison with pulsed-field gel electrophoresis and spa-typing. *PLoS One*. 2009;**4**(4). e5082. doi: [10.1371/journal.pone.0005082](https://doi.org/10.1371/journal.pone.0005082). [PubMed: [19343175](https://pubmed.ncbi.nlm.nih.gov/19343175/)]. [PubMed Central: [PMC2661140](https://pubmed.ncbi.nlm.nih.gov/PMC2661140/)].
  30. Akbari Dehbalaei M, Najar-Peerayeh S, Taherikalani M, Behmanesh M. Clinical isolates of *acinetobacter baumannii* from Tehran hospitals: Pulsed-field gel electrophoresis characterization, clonal lineages, antibiotic susceptibility, and biofilm-forming ability. *Jundishapur J Microbiol*. 2017;**10**(7). e13790. doi: [10.5812/jjm.13790](https://doi.org/10.5812/jjm.13790).
  31. Skally M, Duffy F, Burns K, Doyle D, Foley S, Thomas T, et al. What may be lurking in the hospital undergrowth? Inapparent cross-transmission of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae*. *J Hosp Infect*. 2014;**88**(3):156-61. doi: [10.1016/j.jhin.2014.07.011](https://doi.org/10.1016/j.jhin.2014.07.011). [PubMed: [25280879](https://pubmed.ncbi.nlm.nih.gov/25280879/)].
  32. Hall JM, Corea E, Sanjeevani HD, Inglis TJ. Molecular mechanisms of beta-lactam resistance in carbapenemase-producing *Klebsiella pneumoniae* from Sri Lanka. *J Med Microbiol*. 2014;**63**(Pt 8):1087-92. doi: [10.1099/jmm.0.076760-0](https://doi.org/10.1099/jmm.0.076760-0). [PubMed: [24855071](https://pubmed.ncbi.nlm.nih.gov/24855071/)].
  33. Aqel AA, Meunier D, Alzoubi HM, Masalha IM, Woodford N. Detection of CTX-M-type extended-spectrum beta-lactamases among Jordanian clinical isolates of Enterobacteriaceae. *Scand J Infect Dis*. 2014;**46**(2):155-7. doi: [10.3109/00365548.2013.835069](https://doi.org/10.3109/00365548.2013.835069). [PubMed: [24069912](https://pubmed.ncbi.nlm.nih.gov/24069912/)].